Melanoma
News and reporting on melanoma.
Castle Biosciences Q3 Revenues up 39 Percent
The company saw growth across its melanoma, squamous cell carcinoma, Barrett's esophagus, and pharmacogenomics tests.
Several new studies appear to confirm the test's potential to prevent overtreatment of melanoma patients while identifying those at high risk.
DermTech Sells Assets, Becomes Private Company
Derm-Jes had acquired substantially all DermTech assets through a court-approved auction following DermTech's bankruptcy filing in June.
DermTech Files for Bankruptcy, Lays off 20 Percent of Workforce
The firm intends to continue its laboratory operations and processing orders for its melanoma test while selling almost all of its assets.
Castle Biosciences Builds Skin Cancer Assay Data, Eyes Future Expansion as Q1 Sales Jump 74 Percent
Premium
The company highlighted clinical research progress for its two skin cancer tests and said it hopes to expand in the gastrointestinal cancer space in coming years.